Canagliflozin may reduce gout flare risk in people with type 2 diabetes

Treatment with the sodium-glucose cotransporter-2 inhibitor canagliflozin is associated with a reduction in serum urate concentration and gout flare risk among patients with type 2 diabetes, suggests a post-hoc analysis of the CANVAS Program trial.

Read the full article here

Related Articles